Global End Stage Renal Disease Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Treatment;
Transplantation and Dialysis - Peritoneal Dialysis, Hemodialysis, and Wearable Artificial Kidney.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global End Stage Renal Disease Market (USD Million), 2021 - 2031
In the year 2024, the Global End Stage Renal Disease Market was valued at USD 124,196.34 million. The size of this market is expected to increase to USD 300,427.92 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 13.5%.
The global end-stage renal disease (ESRD) market is expanding rapidly due to the increasing prevalence of chronic kidney disease (CKD) and the rising aging population worldwide. ESRD, the final stage of chronic kidney disease, requires either dialysis or a kidney transplant for patients to survive, leading to high demand for ESRD-related treatments. Factors such as poor lifestyle choices, diabetes, hypertension, and genetic predisposition are contributing to the rising number of ESRD cases globally. With over 700 million people affected by kidney disease worldwide, the demand for renal care services, dialysis machines, and kidney transplants has surged, driving market growth. The aging population is particularly vulnerable to kidney diseases, further exacerbating the market's expansion.
Dialysis is the primary treatment for ESRD, and the market for dialysis products and services constitutes a significant portion of the global ESRD market. Hemodialysis, a procedure where blood is filtered outside the body, remains the most widely used treatment, especially in developed regions. Peritoneal dialysis, which uses the lining of the abdomen to filter waste, is also gaining traction, particularly in homecare settings. Advancements in dialysis technologies, including the development of more efficient machines, wearable dialysis devices, and portable solutions, are contributing to market growth. Moreover, the increasing number of dialysis centers and government initiatives to improve access to renal care are helping drive the adoption of dialysis treatments, particularly in emerging markets.
Despite the advancements in treatment options, the global ESRD market faces several challenges, including the high cost of dialysis and the shortage of kidney donors for transplants. As dialysis requires long-term management, the ongoing costs place a significant financial burden on both patients and healthcare systems. While kidney transplantation offers a better long-term prognosis, the global shortage of transplantable organs limits the availability of this treatment option. However, innovations in kidney transplant technologies, such as the development of artificial kidneys, along with the rise of home dialysis and remote monitoring, are expected to offer new opportunities in the ESRD market. Additionally, the increasing focus on preventive healthcare, early diagnosis, and the management of risk factors such as diabetes and hypertension offers potential avenues to mitigate the rise in ESRD cases in the future.
Global End Stage Renal Disease Market Recent Developments
-
In January 2023, Baxter outlined strategic initiatives to enhance operational efficiency, drive innovation for patients, and boost shareholder value. The company plans to spin off its renal care and acute treatments global business units into a separate, publicly traded entity within 12-18 months.
-
In April 2021, Baxter received U.S. FDA Emergency Use Authorization (EUA) for its Oxiris Blood Purification Filter set, designed for COVID-19 patients in ICU with confirmed or imminent respiratory failure requiring blood purification therapy.
Segment Analysis
The Global End Stage Renal Disease Market has been segmented by Treatment and Geography. In terms of treatment, the market includes dialysis (hemodialysis and peritoneal dialysis) and kidney transplantation. Dialysis remains the most common treatment for ESRD, as it helps to artificially filter waste and excess fluid from the blood when the kidneys can no longer perform these functions. Hemodialysis is typically performed in healthcare settings, while peritoneal dialysis can be done at home, providing patients with more flexibility. Kidney transplantation, though a more permanent solution, is limited by donor availability and is often pursued after patients have undergone extensive dialysis treatment.
Geographically, the ESRD market is dominated by North America and Europe, where advanced healthcare infrastructure and high awareness of kidney diseases lead to high demand for dialysis treatments and kidney transplants. The United States, in particular, has a large population of ESRD patients, with a significant number undergoing dialysis, especially given the high prevalence of diabetes and hypertension—primary risk factors for kidney failure. In these regions, the ESRD market benefits from established healthcare systems that provide both medical treatments and advanced surgical options like kidney transplantation.
The Asia-Pacific region, including countries like China, India, and Japan, is also experiencing substantial growth in the ESRD market due to a rising incidence of chronic kidney disease (CKD), improvements in healthcare infrastructure, and increasing access to dialysis. As the population ages and lifestyle diseases become more prevalent in emerging markets, the demand for ESRD treatments such as dialysis and kidney transplantation is expected to rise. In these regions, both government and private healthcare providers are focusing on expanding dialysis centers and improving transplant services, further fueling market growth in Asia-Pacific.
Global End Stage Renal Disease Segment Analysis
In this report, the Global End Stage Renal Disease Market has been segmented by Treatment and Geography.
Global End Stage Renal Disease Market, Segmentation by Treatment
The Global End Stage Renal Disease Market has been segmented by Treatment into Transplantation and Dialysis.
Dialysis remains the dominant treatment option for ESRD patients due to its widespread use and the increasing number of patients requiring regular renal replacement therapy. Dialysis can be further divided into hemodialysis and peritoneal dialysis, with hemodialysis being the most commonly performed procedure. Hemodialysis involves filtering the blood outside the body using a machine, typically conducted at dialysis centers. As of now, hemodialysis accounts for the largest market share due to its established infrastructure and the high number of patients who require it. On the other hand, peritoneal dialysis, which uses the lining of the abdomen to filter waste, has seen growing demand, especially in home care settings, as it provides more flexibility and independence for patients.
Kidney transplantation is considered the gold standard treatment for ESRD, offering better long-term outcomes compared to dialysis. A successful kidney transplant allows patients to resume a near-normal lifestyle without the need for continuous dialysis. However, kidney transplantation is limited by a shortage of available donor organs, which creates a bottleneck in the treatment process. As a result, despite the better prognosis, only a fraction of ESRD patients receive a transplant due to this shortage. The transplantation market is driven by advancements in immunosuppressive therapies, which help prevent organ rejection, and ongoing developments in transplant technologies. Additionally, initiatives to improve organ donation and transplant access are contributing to the growth of the transplant market.
The dialysis segment is expected to continue its dominance in the global ESRD market, given the immediate need for renal replacement therapy and the lack of sufficient donor kidneys for transplantation. Despite the higher long-term costs associated with dialysis, its ability to provide essential life support to patients with end-stage kidney failure makes it an indispensable treatment. However, innovations in home dialysis and portable dialysis solutions, as well as wearable artificial kidneys, are shaping the future of dialysis treatments by offering patients more convenient and flexible options. Meanwhile, the kidney transplant market faces challenges related to donor organ availability, but ongoing developments in areas like bioengineering and artificial organs could offer promising solutions to meet the demand for transplants, thereby balancing the two treatment modalities over time.
Global End Stage Renal Disease Market, Segmentation by Geography
In this report, the Global End Stage Renal Disease Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global End Stage Renal Disease Market Share (%), by Geographical Region, 2024
The global end-stage renal disease (ESRD) market is geographically diverse, with North America holding the largest share due to the high prevalence of chronic kidney diseases (CKD) and the well-established healthcare infrastructure in the region. The United States, in particular, has a large ESRD patient population, primarily due to high rates of diabetes, hypertension, and obesity, which are major risk factors for CKD. The presence of advanced renal care technologies, numerous dialysis centers, and government-funded programs like Medicare, which cover ESRD treatment, significantly contributes to the market share. In addition, the high demand for both dialysis and kidney transplantation treatments in North America further solidifies its dominant position in the global ESRD market.
Europe also holds a significant share of the global ESRD market, driven by the increasing aging population and the prevalence of kidney diseases. Countries like Germany, France, and the UK have robust healthcare systems that support widespread dialysis access and kidney transplant programs. Moreover, the rising incidence of CKD across Europe, combined with an increasing focus on early diagnosis and preventative care, is expected to contribute to continued growth in the region. The availability of dialysis treatments and advanced healthcare infrastructure in Europe ensures that patients with ESRD have access to appropriate care, further bolstering the market in this region.
The Asia-Pacific region is experiencing the fastest growth in the global ESRD market, fueled by the rising prevalence of diabetes, hypertension, and an aging population. Countries such as China, India, Japan, and South Korea are seeing increasing rates of ESRD, driving demand for both dialysis and kidney transplantation services. While dialysis remains the primary treatment option in many Asia-Pacific countries, advancements in healthcare infrastructure and the adoption of more efficient dialysis technologies are supporting market expansion. Additionally, the growing emphasis on improving organ donation systems and expanding access to kidney transplantation treatments is expected to further contribute to the market's growth in the region. With improvements in healthcare access and the rising prevalence of risk factors, the Asia-Pacific region is projected to become an even more significant player in the global ESRD market.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global End Stage Renal Disease Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing prevalence of chronic kidney disease (CKD) and diabetes
- Rising aging population and associated health risks
- Advancements in dialysis technologies
- Growing healthcare infrastructure and dialysis centers
The growing healthcare infrastructure, particularly in emerging markets, is a major driver of the global end-stage renal disease (ESRD) market. As the prevalence of chronic kidney diseases (CKD) continues to rise, many developing countries are investing heavily in improving their healthcare systems to accommodate the growing number of ESRD patients. This includes expanding hospital facilities, upgrading medical equipment, and enhancing the capacity of healthcare professionals trained to manage kidney-related conditions. The expansion of healthcare infrastructure is especially evident in regions like Asia-Pacific, Latin America, and the Middle East, where governments are increasingly recognizing the importance of renal care and are working to build robust healthcare systems to treat ESRD more effectively.
Dialysis centers, which play a critical role in the treatment of ESRD, are seeing significant growth in response to the rising demand for dialysis services. These centers are essential in providing life-saving treatment to patients with end-stage kidney failure, and their expansion is crucial to meeting the needs of the growing ESRD patient population. Many countries are increasing the number of specialized dialysis centers, which are equipped with state-of-the-art machines and staffed by trained nephrologists and nurses. This increase in dialysis centers is helping to reduce the strain on hospitals and providing patients with more accessible treatment options. Furthermore, the development of outpatient dialysis centers, particularly in urban and suburban areas, is making it easier for patients to receive regular dialysis sessions without having to travel long distances.
In addition to traditional dialysis centers, there is also a growing focus on home dialysis programs, which are being integrated into healthcare systems in response to patient demand for more flexible and personalized care. With advancements in portable dialysis machines and telemedicine, patients can receive dialysis at home, reducing their need to visit clinics frequently. This model of care not only provides patients with greater convenience and comfort but also helps reduce the burden on healthcare facilities. As healthcare infrastructure continues to evolve, the growth of both traditional and home-based dialysis centers is expected to play a significant role in improving access to care for ESRD patients and supporting the ongoing expansion of the global ESRD market.
Restraints
- High treatment costs of dialysis and kidney transplants
- Shortage of kidney donors for transplantation
- Limited access to renal care in low-income regions
- Risk of complications and side effects in dialysis treatments
Dialysis treatments, while life-saving for end-stage renal disease (ESRD) patients, come with a range of risks and potential complications that can impact patient outcomes. One of the primary risks associated with hemodialysis is vascular access complications. In this procedure, blood is withdrawn and filtered through an external machine before being returned to the body, typically through a vascular access point in the arm. Over time, repeated use of these access points can lead to infection, clotting, and blood vessel damage, which can impair the effectiveness of dialysis and necessitate surgical interventions to correct the access site. These complications can lead to hospitalization, extended treatment periods, or even the need for alternative access methods like a central venous catheter, which comes with its own risks.
Another significant risk of dialysis is dialysis-related hypotension, which occurs when the blood pressure drops too low during treatment. Hemodialysis can cause rapid shifts in fluid and electrolytes, leading to a sudden drop in blood volume, causing dizziness, nausea, and fainting. In more severe cases, this condition can result in cardiovascular events, such as arrhythmias or heart failure, particularly in patients who already have pre-existing heart conditions. Although fluid management techniques and better dialysis machines have helped mitigate this risk, it remains one of the most common complications faced by patients undergoing regular dialysis.
Peritoneal dialysis, while offering more flexibility for patients and the option of home care, also comes with specific risks. Since the procedure involves introducing a dialysis solution into the abdomen, there is a risk of peritonitis, an infection of the peritoneal cavity. This can lead to symptoms such as abdominal pain, fever, and nausea, and if left untreated, it can result in severe complications that require hospitalization. Other side effects of peritoneal dialysis include weight gain due to the absorption of glucose from the dialysis fluid and fluid imbalance, which can lead to both dehydration and fluid overload if not carefully managed. Despite these risks, advances in dialysis technology, better infection control practices, and regular monitoring help to mitigate these complications, though they remain a challenge in the management of ESRD.
Opportunities
- Innovations in artificial kidneys and bioengineered organs
- Growth of home dialysis and portable dialysis solutions
- Early detection and management of kidney diseases
- Expansion of healthcare access in emerging markets
The expansion of healthcare access in emerging markets is crucial for addressing the growing burden of end-stage renal disease (ESRD) and improving patient outcomes in regions where kidney diseases are becoming more prevalent. As emerging economies like India, China, and countries in Latin America and Sub-Saharan Africa experience rising rates of chronic conditions such as diabetes and hypertension, which are key risk factors for ESRD, there is an increasing demand for renal care services. Governments in these regions are recognizing the need to improve healthcare infrastructure, invest in modern medical technologies, and enhance the availability of specialized care, such as dialysis centers and kidney transplantation facilities. These improvements are vital in ensuring that ESRD patients receive the appropriate treatment without having to travel long distances or face financial barriers.
One of the key elements in expanding healthcare access is the increase in the number of dialysis centers and renal care units in emerging markets. These centers are being established to provide essential dialysis treatments to growing patient populations, particularly in rural or underserved areas. With the expansion of government health programs, more funding is being allocated to subsidize the cost of dialysis and kidney transplants, making these treatments more affordable for low- and middle-income populations. Additionally, the development of home dialysis options and portable dialysis machines is further improving access, as these solutions allow patients to manage their care at home, reducing the strain on hospital facilities and making treatment more accessible to remote communities.
The rise in healthcare access in emerging markets is also spurring growth in education and training for healthcare professionals specializing in kidney care. The establishment of more training programs for nephrologists, dialysis nurses, and other specialists is crucial in ensuring a skilled workforce capable of providing high-quality care to ESRD patients. Along with expanding healthcare infrastructure, there is a growing focus on preventative care and early detection of kidney disease to reduce the incidence of ESRD in the first place. Public health campaigns and education on managing risk factors like diabetes, hypertension, and obesity are also playing an important role in raising awareness and promoting healthier lifestyles. As healthcare systems continue to improve, the availability and quality of renal care in emerging markets will likely expand, helping to reduce the global burden of ESRD.
Competitive Landscape Analysis
Key players in Global End Stage Renal Disease Market include,
- Medtronic
- Fresenius Medical Care AG & Co
- Kgaa
- B. Braun Melsungen AG
- Baxter International Inc
- Asahi Kasei Medical Co Ltd
- Cantel Medical Bd Nikkiso Co
- JMS Co Ltd
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Region
- Global End Stage Renal Disease Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing prevalence of chronic kidney disease (CKD) and diabetes
- Rising aging population and associated health risks
- Advancements in dialysis technologies
- Growing healthcare infrastructure and dialysis centers
- Restraints
- High treatment costs of dialysis and kidney transplants
- Shortage of kidney donors for transplantation
- Limited access to renal care in low-income regions
- Risk of complications and side effects in dialysis treatments
- Opportunities
- Innovations in artificial kidneys and bioengineered organs
- Growth of home dialysis and portable dialysis solutions
- Early detection and management of kidney diseases
- Expansion of healthcare access in emerging markets
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global End Stage Renal Disease Market, By Treatment, 2021 - 2031 (USD Million)
- Transplantation
- Dialysis
- Peritoneal Dialysis
- Hemodialysis
- Wearable Artificial Kidney
- Global End Stage Renal Disease Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global End Stage Renal Disease Market, By Treatment, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
-
Medtronic
-
Fresenius Medical Care AG & Co
-
Kgaa
-
B. Braun Melsungen AG
-
Baxter International Inc
-
Asahi Kasei Medical Co Ltd
-
Cantel Medical Bd Nikkiso Co
-
JMS Co Ltd
-
- Company Profiles
- Analyst Views
- Future Outlook of the Market